Global Health Ventures to Initiate Human Clinical Trials in Europe for X-Excite, Its Male Sexual Enhancement Drug

VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 24, 2010) - Global Health Ventures Inc. (OTCBB: GHLV), or the “Company”, is pleased to announce that it has engaged Clinical Investigations Ltd. of United Kingdom to design and carry out the human clinical trials for X-Excite in Europe under the European Regulatory Guidelines (EMEA). The study is designed to compare three doses of X-Excite with the current oral formulation of sildenafil citrate (Viagra®) in a randomized open labeled study. The focus of the study will be to obtain Pharmacokinetics, bioavailability, and the efficacy of X-Excite in comparison with the existing Viagra® tablets. These trials which will be conducted in patients with erectile dysfunction shall set up the basis for a larger and more comprehensive trial in North America under the FDA guidelines. The Company shall make announcements on the patient’s enrolment, and timeline for the results of these clinical trials.

“We are very pleased that our product, X-Excite is now entering human clinical trials, a significant milestone in the development and progression of this drug. We now can move aggressively forward towards regulatory approval and eventual marketing of our drug, X-Excite,” said Dr. Hassan Salari, Global Health President and CEO.

About X-Excite

X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. Life style products, such as Viagra™, Cialis™ and Levitra™, etc are highly lucrative (nearly $5 billion), products for pharmaceutical companies. This lucrative market will continue to grow for the foreseeable future. The arrival of our new drug (X-Excite) with its fewer side effects and the rapid mode of action meets and will exceed the markets needs.

About Global Health Ventures

The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products... Investors are encouraged to review the risk factors listed or described from time to time in the Company’s filings (10K) with the Securities and Exchange Commission.